Was Peter Altman’s BCDA share purchase under a Rule 10b5-1 trading plan?

The Form 4 indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan. The document’s Rule 10b5-1 checkbox is explicitly unchecked, meaning the August 17, 2026 purchase was not reported as pre-arranged under such a plan.

BioCardia (BCDA) CEO buys 5,400 shares in open market

Q: What insider transaction did BCDA report in this Form 4?

BioCardia (BCDA) reported that CEO Peter Altman purchased 5,400 shares of common stock on August 17, 2026. The shares were acquired in an open-market or private transaction at a weighted average price of $0.93 per share , according to the Form 4.

Q: How many BCDA shares did Peter Altman buy and at what average price?

Peter Altman bought 5,400 BCDA shares at a weighted average price of $0.93 per share . A footnote explains the purchase was executed in multiple trades, with individual prices ranging from $0.92 to $0.97 per share .

Q: What price range did the BCDA insider trades occur at on August 17, 2026?

The BCDA insider trades occurred in a price range of $0.92 to $0.97 per share . The Form 4 reports a weighted average purchase price of $0.93 per share for the 5,400 shares acquired by CEO Peter Altman that day.

Q: How many BCDA shares does Peter Altman own after this transaction?

After the reported purchase, Peter Altman directly owns 381,115 shares of BioCardia common stock. This post-transaction holding figure is disclosed in the Form 4 as the total number of shares beneficially owned following the August 17, 2026 transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) reported that its President and CEO, Peter Altman, purchased 5,400 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted average price of $0.93 per share. The trade was executed in multiple transactions between $0.92 and $0.97 per share, and Altman now directly holds 381,115 shares of BioCardia common stock. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 5,400 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,400 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock ^F1	5,400	$0.93	$5K

Holdings After Transaction: Common Stock — 381,115 shares (Direct)

Footnotes (1)

F1. This transaction was executed in multiple trades ranging from $0.92 to $0.97 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased: 5,400 shares Weighted average purchase price: $0.93 per share Trade price range: $0.92–$0.97 per share +2 more

5 metrics

Shares purchased 5,400 shares Common stock acquired by Peter Altman on August 17, 2026

Weighted average purchase price $0.93 per share Weighted average price for the 5,400 BCDA shares purchased

Trade price range $0.92–$0.97 per share Range of individual trade prices for the August 17, 2026 purchases

Shares owned after transaction 381,115 shares BioCardia common shares directly owned by Peter Altman following the purchase

Net buy transactions 1 transaction; 5,400 net shares bought Summary of non-derivative transactions reported in this Form 4

Key Terms

weighted average per share sales price, open market or private transaction, beneficially owned

3 terms

open market or private transaction financial

"transaction code description: Purchase in open market or private transaction"

beneficially owned financial

"total number of shares beneficially owned following the reported transaction"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

What insider transaction did BCDA report in this Form 4?

BioCardia (BCDA) reported that CEO Peter Altman purchased 5,400 shares of common stock on August 17, 2026. The shares were acquired in an open-market or private transaction at a weighted average price of $0.93 per share, according to the Form 4.

How many BCDA shares did Peter Altman buy and at what average price?

Peter Altman bought 5,400 BCDA shares at a weighted average price of $0.93 per share. A footnote explains the purchase was executed in multiple trades, with individual prices ranging from $0.92 to $0.97 per share.

What price range did the BCDA insider trades occur at on August 17, 2026?

The BCDA insider trades occurred in a price range of $0.92 to $0.97 per share. The Form 4 reports a weighted average purchase price of $0.93 per share for the 5,400 shares acquired by CEO Peter Altman that day.

How many BCDA shares does Peter Altman own after this transaction?

After the reported purchase, Peter Altman directly owns 381,115 shares of BioCardia common stock. This post-transaction holding figure is disclosed in the Form 4 as the total number of shares beneficially owned following the August 17, 2026 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 12:14 PM Accepted by SEC EDGAR 08/18/2026 - 12:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last)

(First)

(Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE

CALIFORNIA

94085

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		P		5,400⁽¹⁾	A	$0.93⁽¹⁾	381,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.92 to $0.97 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ Peter Altman	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR